Document is current
Any future updates will be listed below
-
Authors
Builes-Montaño, Carlos E. https://orcid.org/0000-0002-2418-6159
Contreras-Saldarriaga, Jorge Eduardo https://orcid.org/0000-0002-0187-8232
Arroyo-Ripoll, Oriana https://orcid.org/0000-0003-0136-2567
Donado-Gomez, Jorge Hernando https://orcid.org/0000-0001-8581-2267
- License Information
-
More Information
Article History
Received: 12 December 2024
Accepted: 5 February 2026
First Online: 11 March 2026
Declarations
:
: No informed consent or Institutional Review Board approval was needed due to the nature of this research.
: All authors approved the final version of this manuscript and its publication.
: Jorge E. Contreras-Saldarriaga has received speaker fees from Ipsen. Carlos E. Builes-Montaño has received consulting or speaker fees from Sanofi, Novo Nordisk, Novartis, Recordati Rare Diseases, Amgen, Ipsen and Boehringer Ingelheim. The other authors certify that they have no affiliation nor are they involved with any organization or entity with any financial interest (such as fees, financial aid for education, shares, employment contracts, work as consultants, or any other type of interest) or non-financial interest (such as personal, professional relationships, affiliations, or beliefs) in the topic of interest or any material discussed in this manuscript.
